Statement of Changes in Beneficial Ownership (4)
July 09 2020 - 4:28PM
Edgar (US Regulatory)
FORM 4
[ ]
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0287
Estimated average burden hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
1. Name and Address of Reporting Person
*
HIGGINS JOHN L |
2. Issuer Name and Ticker or Trading Symbol
LIGAND PHARMACEUTICALS INC
[
LGND
]
|
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
__X__ Director _____ 10% Owner __X__ Officer (give title below) _____ Other (specify below) Chief Executive Officer |
(Last)
(First)
(Middle)
3911 SORRENTO VALLEY BOULEVARD, STE 110 |
3. Date of Earliest Transaction
(MM/DD/YYYY)
7/7/2020 |
(Street)
SAN DIEGO, CA 92121
(City)
(State)
(Zip)
|
4. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line)
_X
_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
|
1.Title of Security (Instr. 3)
|
2. Trans. Date
|
2A. Deemed Execution Date, if any
|
3. Trans. Code (Instr. 8)
|
4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)
|
5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)
|
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)
|
7. Nature of Indirect Beneficial Ownership (Instr. 4)
|
Code
|
V
|
Amount
|
(A) or (D)
|
Price
|
Common Stock | 7/7/2020 | | M | | 1165 | A | $85.79 | 201421 | D | |
Common Stock | 7/7/2020 | | M | | 1777 | A | $56.26 | 203198 | D | |
Common Stock | 7/7/2020 | | M | | 1373 | A | $74.42 | 204571 | D | |
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Trans. Date | 3A. Deemed Execution Date, if any | 4. Trans. Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) |
Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares |
Employee Stock Option (right to buy) | $56.26 | 7/7/2020 | 7/7/2020 | M | | | 1777 | (1) | 2/10/2025 | Common Stock | 1777 | $0.0 | 54421 | D | |
Employee Stock Option (right to buy) | $74.42 | 7/7/2020 | 7/7/2020 | M | | | 1373 | (2) | 2/12/2024 | Common Stock | 1373 | $0.0 | 93627 | D | |
Employee Stock Option (right to buy) | $85.79 | 7/7/2020 | 6/30/2020 | M | | | 1165 | (3) | 2/11/2026 | Common Stock | 1165 | $0.0 | 54226 | D | |
Explanation of Responses: |
(1) | Grant to reporting person of options, exercisable over a 4-year period measured from the date of grant, 12-1/2% after six months, then 1/48th of the Option Shares per month thereafter. The date of grant was 02/10/15. |
(2) | Grant to reporting person of options, exercisable over a 4-year period measured from the date of grant, 12-1/2% after six months, then 1/48th of the Option Shares per month thereafter. The date of grant was 02/12/14. |
(3) | Grant to reporting person of options to purchase shares of common stock ("Option Shares"), exercisable over a 4-year period measured from the date of grant, 12-1/2% after six months, then 1/48th of the Option Shares per month thereafter. The date of grant was 02/11/16. |
Reporting Owners
|
Reporting Owner Name / Address | Relationships |
Director | 10% Owner | Officer | Other |
HIGGINS JOHN L 3911 SORRENTO VALLEY BOULEVARD, STE 110 SAN DIEGO, CA 92121 | X |
| Chief Executive Officer |
|
Signatures
|
By: Charles S.Berkman For: John L. Higgins | | 7/9/2020 |
**Signature of Reporting Person | Date |
Ligand Pharmaceuticals (NASDAQ:LGND)
Historical Stock Chart
From Apr 2024 to May 2024
Ligand Pharmaceuticals (NASDAQ:LGND)
Historical Stock Chart
From May 2023 to May 2024